Lin BioScience (ROCO:6696) Total Stockholders Equity : NT$1,271.79 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience Total Stockholders Equity?

Lin BioScience's Total Stockholders Equity for the quarter that ended in Jun. 2023 was NT$1,271.79 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Lin BioScience's Book Value per Share for the quarter that ended in Jun. 2023 was NT$17.31. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Lin BioScience's Debt-to-Equity for the quarter that ended in Jun. 2023 was 0.04.

Lin BioScience Total Stockholders Equity Historical Data

The historical data trend for Lin BioScience's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lin BioScience Total Stockholders Equity Chart

Lin BioScience Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

141.81

912.34

541.57

1,234.16

2,137.38

Lin BioScience Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial										541.57	1,444.76	1,234.16	1,271.79	2,137.38

Lin BioScience (ROCO:6696) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Lin BioScience's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1271.793	-	0)	/	73.49
	=	17.31

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Lin BioScience's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(13.484	+	36.51)	/	1271.793
	=	0.04

Lin BioScience Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Lin BioScience's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lin BioScience (ROCO:6696) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110

Website

https://www.linbioscience.com

Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience (ROCO:6696) Headlines

No Headlines